O11 Change in function, fatigue and pain in anti-CCP positive at-risk individuals predict progression to inflammatory arthritis

Extract

Background: Functional limitations may begin in the pre-clinical phase of rheumatoid arthritis (RA). We explored the association of changes in reported function, fatigue and pain in a cohort of people with antibodies to cyclic citrullinated peptides (CCP) with progression to inflammatory arthritis (IA).

Methods: Yorkshire patients presenting in the community or to secondary care with a new musculoskeletal complaint were offered anti-CCP2 testing. 205 anti-CCP positive people without clinical synovitis, recruited between June 2008 and August 2016, had either been followed for at least 12 months, or had progressed to IA. Clinical assessments, Health Assessment Questionnaires (HAQ) and Visual Analogue Scores (VAS) of fatigue and pain were completed every three months for 12 months. Latent growth curve models were used to describe change in HAQ and VAS over time, then the models were applied as covariates in separate cox regression analyses, to describe the relationship between change in HAQ, fatigue and pain VAS, and development of IA within 12 months.